Health

Breathing in a new era: a comparative analysis of lung cancer policies in Japan, South Korea and Taiwan

May 29, 2024

Global

Breathing in a new era: a comparative analysis of lung cancer policies in Japan, South Korea and Taiwan

May 29, 2024

Global
Neeladri Verma

Manager, Health Policy and Insights at Economist Impact

Neeladri Verma is a manager with Economist Impact's Health team. She leads customised research projects for international healthcare clients, from ideation to execution. She works with multiple stakeholders and manages multidisciplinary teams, conducting quantitative and qualitative analyses across health priority themes.

Dr Verma has a rich and diverse background in health and research, focusing primarily on the Asian markets. A dental doctor by trade, she also holds an MBA from the University of Hong Kong. Prior to joining Economist Impact, she worked as a consultant at a boutique healthcare management consulting firm in Hong Kong, conducting research and strategic analyses on topics such as vaccine procurement, the role of the private sector in health reforms, health system appraisals, and multisectoral approaches to health policy.

Breathing in a new era: a comparative analysis of lung cancer policies in Japan, South Korea and Taiwan

Lung cancer is the most fatal cancer worldwide. By 2050 the global burden of lung cancer is projected to increase to 3.8m new cases and 3.2m deaths per year, with the greatest burden expected in East Asia, at 1.7m new cases and 1.5m deaths.1

The Economist Impact report, "Breathing in a new era: a comparative analysis of lung cancer policies in Japan, South Korea and Taiwan," sponsored by MSD, evaluates the various policies impacting lung cancer care in the three countries under the following five domains:

  • Lung cancer is a strategic priority: focusing on national cancer control plans and clinical guidelines
  • Lung cancer is a public health issue: covering health literacy, tobacco control and screening
  • Lung cancer is a race against time: reviewing rapid referral pathways and fast-track referral processes to diagnosis and treatment
  • Lung cancer is at a crossroads: assessing effective treatment and quality care
  • Lung cancer is a focus for research: appraising cancer registries and research and development initiatives

 

The report uncovers the advancements in lung cancer care and policy changes in Japan, South Korea and Taiwan since our last report and identifies areas for further growth. We have identified the following four calls to action for these countries to improve lung cancer care and patient outcomes:

  1. Improve tobacco control and air quality management
  2. Identify the truly high-risk population for targeted screening
  3. Bridge inequities and improve access to comprehensive care
  4. Advance translational research in lung cancer among never-smokers

References

1 Sharma R. Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050. Int J Clin Oncol. 2022 Apr;27(4):665-675. doi: 10.1007/s10147-021-02108-2. Epub 2022 Jan 12. PMID: 35020103; PMCID: PMC8753949.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week